Telix Pharmaceuticals (Est) Pty. Ltd. Sustainability Profile
Telix Pharmaceuticals (Est) Pty. Ltd., headquartered in Australia, is a pioneering biopharmaceutical company focused on the development of innovative cancer therapies and diagnostic imaging solutions. Founded in 2015, Telix has rapidly established itself in the oncology sector, with a strong emphasis on radiopharmaceuticals that target specific cancer types. The company operates primarily in Australia, Europe, and North America, offering unique products such as TLX591 (a prostate cancer imaging agent) and TLX250 (for renal cancer). These therapies leverage advanced radiolabelled technology, setting Telix apart in a competitive market. With a commitment to improving patient outcomes, Telix Pharmaceuticals has achieved significant milestones, including successful clinical trials and strategic partnerships, solidifying its position as a leader in the field of targeted cancer treatment.
DitchCarbon Score
How does Telix Pharmaceuticals (Est) Pty. Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Telix Pharmaceuticals (Est) Pty. Ltd.'s score of 16 is lower than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Telix Pharmaceuticals (Est) Pty. Ltd.'s reported carbon emissions
Telix Pharmaceuticals (Est) Pty. Ltd., headquartered in Australia, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Telix Pharmaceuticals Limited, which may influence its climate commitments and reporting practices. As of now, there are no documented reduction targets or climate pledges from Telix Pharmaceuticals (Est) Pty. Ltd. This lack of specific initiatives suggests that the company may still be in the early stages of developing its climate strategy or reporting framework. Given the absence of direct emissions data and reduction initiatives, it is essential to consider the broader industry context. Many pharmaceutical companies are increasingly focusing on sustainability and carbon reduction, often setting Science-Based Targets (SBTi) to align with global climate goals. However, without specific commitments or data from Telix Pharmaceuticals (Est) Pty. Ltd., it remains unclear how they plan to address their carbon footprint or contribute to climate action. In summary, while Telix Pharmaceuticals (Est) Pty. Ltd. does not currently provide emissions data or reduction targets, its affiliation with Telix Pharmaceuticals Limited may play a role in shaping its future climate commitments.
How Carbon Intensive is Telix Pharmaceuticals (Est) Pty. Ltd.'s Industry?
How Carbon Intensive is Telix Pharmaceuticals (Est) Pty. Ltd.'s Location?
Telix Pharmaceuticals (Est) Pty. Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Telix Pharmaceuticals (Est) Pty. Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
